Arrowhead Research
ARWR
$72.69
-6.75%
Arrowhead Pharmaceuticals Inc. is a biotechnology company focused on developing RNA interference (RNAi) therapeutics to treat diseases with a genetic origin, particularly those characterized by the overproduction of specific proteins. The company is a recognized leader in the RNAi space, distinguished by its proprietary Targeted RNAi Molecule (TRiM) platform, which enables precise delivery of therapies to target tissues like the liver. The current investor narrative is dominated by the commercial and clinical progress of its lead liver-targeted programs, with recent quarterly results showing a dramatic 105% year-over-year revenue surge, likely driven by milestone payments and partnerships, fueling debate over the sustainability of this growth and the path to profitability.…
ARWR
Arrowhead Research
$72.69
Related headlines
ARWR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Arrowhead Research's 12-month outlook, with a consensus price target around $94.50 and implied upside of +30.0% versus the current price.
Average Target
$94.50
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$58 - $95
Analyst target range
Analyst coverage for ARWR appears limited, with data showing only 4 analysts providing estimates for revenue and EPS, and no consensus price target or recommendation data provided in the key inputs. This suggests insufficient analyst coverage is available for a definitive consensus view. The implication is that ARWR, despite its multi-billion dollar market cap, may still be under-followed by the broader sell-side community, which can lead to higher volatility and less efficient price discovery as the stock reacts more to binary clinical data and partnership news. The institutional ratings data shows recent activity is unanimously positive or neutral, with firms like HC Wainwright, B. Riley, and Piper Sandler maintaining 'Buy' or 'Overweight' ratings, while Goldman Sachs and Morgan Stanley have 'Neutral' or 'Equal Weight' stances, indicating a generally favorable but cautiously optimistic institutional view.
Bulls vs Bears: ARWR Investment Factors
The bull case, driven by explosive revenue growth, a strong balance sheet, and powerful technical momentum, currently holds stronger evidence, as reflected in the stock's 432% annual gain and proximity to its 52-week high. However, the bear case presents severe and fundamental risks centered on unsustainable, lumpy earnings and an extreme valuation that demands flawless execution. The single most important tension in the investment debate is the sustainability of revenue growth: if ARWR can transition its partnership-driven, volatile income into a more predictable commercial or milestone stream, the bull thesis is validated; if revenue reverts to the sub-$30 million levels seen in recent quarters, the current valuation will prove unsustainable, triggering a significant correction.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 105% year-over-year to $264 million, demonstrating strong partnership and milestone execution. This follows a similarly strong Q4 2025 with $256.5 million in revenue, indicating a potential shift towards more consistent high-value collaboration income.
- Robust Financial Position: The company has a strong current ratio of 4.86 and free cash flow (TTM) of $322 million, providing ample liquidity to fund its clinical pipeline. With a manageable debt-to-equity ratio of 0.79, ARWR is not facing immediate financing pressure, a key advantage for a clinical-stage biotech.
- Powerful Technical Momentum: The stock is up 432.8% over the past year and trades at 97% of its 52-week high ($76.76), indicating sustained bullish momentum. The 1-month relative strength of +8.9% vs. the S&P 500 suggests the uptrend remains intact despite recent consolidation.
- Platform Leadership in RNAi: ARWR's proprietary TRiM platform for liver-targeted RNAi therapeutics provides a competitive moat. The company's focus on diseases of protein overproduction, validated by recent partnership revenues, underscores the platform's commercial and scientific potential.
Bearish
- Extremely Volatile & Lumpy Earnings: Profitability is highly inconsistent, with Q1 2026 net income of $30.8 million followed by a Q4 2025 loss of -$23.8 million. Trailing EPS is negative at -$0.00035, and the forward P/E is -16.6, reflecting a lack of stable core earnings.
- Revenue Sustainability Concerns: Revenue is driven by lumpy milestone payments, as seen in the drastic drop from $542.7 million in Q2 2025 to $27.8 million in Q3 2025. This volatility makes forecasting difficult and raises questions about the durability of the recent 105% growth surge.
- Sky-High Valuation Multiples: The stock trades at a trailing P/S of 5.56x and an EV/Sales of 9.23x, which are elevated for a company with unproven earnings consistency. The PEG ratio of 28.35 suggests the market is pricing in near-perfect execution of future growth.
- Extreme Price Volatility & Risk: With a beta of 1.27, the stock is 27% more volatile than the market, and its 52-week range is $12.44 to $76.76, implying a potential -83% drawdown from current levels. A short ratio of 5.82 indicates significant bearish sentiment among short-term traders.
ARWR Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +432.8%. As of the latest close at $74.81, the price is trading at approximately 97% of its 52-week high of $76.76, indicating it is near the peak of its recent range and may be testing a critical resistance level. This positioning suggests strong momentum but also raises the risk of a pullback if the resistance holds. Recent short-term momentum shows signs of consolidation after the massive run; the 1-month price change is +18.9%, which is positive but decelerates from the 3-month gain of +7.9%, indicating a potential pause or digestion of gains. The stock has demonstrated significant volatility, with a beta of 1.27, meaning it is 27% more volatile than the broader market, which is typical for a clinical-stage biotech and necessitates careful risk management. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $76.76 and support at the 52-week low of $12.44; a decisive breakout above resistance could signal a continuation of the bull run, while a failure could lead to a retreat toward the $60-$65 consolidation zone seen in recent months.
Beta
1.29
1.29x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$13-$79
Price range past year
Annual Return
+448.6%
Cumulative gain past year
| Period | ARWR Return | S&P 500 |
|---|---|---|
| 1m | +12.9% | +9.1% |
| 3m | +12.7% | +6.8% |
| 6m | +85.3% | +9.9% |
| 1y | +448.6% | +30.5% |
| ytd | +7.2% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARWR Fundamental Analysis
Revenue growth is explosive but highly volatile, characteristic of a biotech reliant on milestone payments. The most recent quarter (Q1 2026) reported revenue of $264.0 million, representing a 104.6% year-over-year increase. However, this follows a quarter (Q4 2025) with $256.5 million in revenue and a preceding quarter (Q3 2025) with only $27.8 million, highlighting the lumpy nature of partnership-driven income. The company's path to profitability remains inconsistent; the latest quarter showed a net income of $30.8 million (net margin of 11.7%) and a gross margin of 100%, but the prior quarter posted a net loss of -$23.8 million. This volatility underscores that core profitability is not yet stable, as earnings are heavily influenced by non-recurring collaboration revenue. The balance sheet and cash flow position appear robust for funding operations. The company reported free cash flow (TTM) of $322.0 million, a strong current ratio of 4.86, and a manageable debt-to-equity ratio of 0.79. This financial health, combined with a market cap of $4.6 billion, suggests Arrowhead has sufficient liquidity to advance its clinical pipeline without immediate financing needs, a key strength in the capital-intensive biotech sector.
Quarterly Revenue
$264033000.0B
2025-12
Revenue YoY Growth
+104.61%
YoY Comparison
Gross Margin
+1.00%
Latest Quarter
Free Cash Flow
$322007000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARWR Overvalued?
Given the inconsistent profitability (Net Income was positive last quarter but trailing EPS is -$0.00035), the Price-to-Sales (PS) ratio is the most appropriate primary valuation metric. The stock trades at a trailing PS ratio of 5.56x. There is no forward PS provided for peer comparison, but the EV/Sales multiple of 9.23x offers another perspective on enterprise value relative to sales. Compared to industry averages, specific data is not available in the provided dataset, but a PS ratio around 5-6x for a high-growth, platform-based biotech with late-stage assets could be considered reasonable if growth expectations are high. Historically, the stock's own valuation has fluctuated wildly with clinical and financial news. The current PS ratio of 5.56x is significantly lower than the 35.21x seen at the end of Q1 2026 (Dec 2025), which coincided with the peak revenue quarter, suggesting the market has re-rated the stock to a lower multiple as it digests the lumpy revenue stream and looks ahead to sustained commercial execution.
PE
-2828.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -71x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are dominated by extreme earnings volatility and dependence on non-recurring collaboration revenue. The company's net income swung from a $370.4 million profit in Q2 2025 to a $175.2 million loss in Q3 2025, demonstrating a core business model not yet geared toward stable profitability. While the balance sheet is currently strong with $322 million in TTM free cash flow, a sustained period without major partnership milestones could rapidly deplete resources given ongoing high R&D expenses, which were $177 million in the latest quarter. The path to self-sustaining profitability remains unclear and is the primary financial risk.
Market & Competitive Risks are severe, centered on valuation compression and clinical failure. Trading at an EV/Sales of 9.23x and a P/S of 5.56x, ARWR is priced for near-perfect success. Any clinical setback for its lead liver-targeted programs or increased competition in the RNAi space (e.g., from Alnylam) could trigger a rapid de-rating. The stock's beta of 1.27 confirms its high sensitivity to market sentiment, and a broader sector rotation away from high-multiple, pre-profitability biotech stocks would disproportionately impact ARWR. The recent news of accelerating adoption for CRISPR Therapeutics' gene therapy highlights the competitive and innovative intensity of the genetic medicine landscape.
Worst-Case Scenario involves a combination of clinical delays, partnership setbacks, and a broader biotech bear market. The specific chain would be: a key clinical trial misses its primary endpoint, leading a major partner to pause collaboration payments. Concurrently, rising interest rates compress valuation multiples for all growth stocks. This could trigger a sell-off toward the stock's tangible book value support and its 52-week low of $12.44. From the current price of $74.81, this represents a catastrophic downside of approximately -83%. A more realistic, yet severe, bear case might see the stock fall to the $30-$40 range, where it consolidated prior to its recent surge, implying a downside risk of -50% to -60%.